Dozens of patients and families whose lives have been damaged by extremely rare reactions to the Oxford/AstraZeneca Covid vaccine have launched legal action 🔴 PMGallagher1 reports
While the vaccine is widely credited with protecting many millions of people from the virus, more than 80 patients died and 365 suffered severe reactions, some of them resulting in serious injuries as a result of blood clots caused by the jab.
The latest NHS advice is that Covid-19 vaccination is safe and effective and that it gives people the best protection against Covid-19. NHS advice states: “Anyone who gets Covid-19 can become seriously ill or have long-term effects. The Covid-19 vaccines are the best way to protect yourself and others.”
Vaccine-induced immune thrombotic thrombocytopenia affects approximately 1 in 50,000 AstraZeneca vaccine recipients under 50 years old, and 1 in 100,000 for those ages 50 years and older in England, according to the NHS, which saysAstraZeneca vaccinations were first administered on 4 January 2021 as part of a rapid rollout of jabs by the NHS. Just a few weeks earlier, Margaret Keenan, 90, had become the first person in the world to receive the Pfizer jab following its clinical approval.
The scheme provides a one-off tax free payment, currently £120,000, to successful applicants where a vaccine has caused severe disablement. It does not prejudice the right of the disabled person to pursue a claim for damages through the courts. To qualify for a payment, an applicant needs to establish that they meet two main criteria: on the balance of probabilities, the vaccine caused disability, and that the resulting disablement is severe, classified as 60 per cent or more.
It is no longer used in the UK. It has been used in several other countries around the world, but it is uncertain if any stocks are still being used. “These include strokes, heart attacks, amputations and other major life-changing injuries. This is an unusually large number of very serious injuries to have been caused by a vaccine. We expect to be able to establish in court that these clots were likely caused by the vaccine.”
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Post-COVID dyspnea: prevalence, predictors, and outcomes in a longitudinal, prospective cohort - BMC Pulmonary MedicineBackground The pathophysiology, evolution, and associated outcomes of post-COVID dyspnea remain unknown. The aim of this study was to determine the prevalence, severity, and predictors of dyspnea 12 months following hospitalization for COVID-19, and to describe the respiratory, cardiac, and patient-reported outcomes in patients with post-COVID dyspnea. Methods We enrolled a prospective cohort of all adult patients admitted to 2 academic hospitals in Vancouver, Canada with PCR-confirmed SARS-CoV-2 during the first wave of COVID between March and June 2020. Dyspnea was measured 3, 6, and 12 months after initial symptom onset using the University of California San Diego Shortness of Breath Questionnaire. Results A total of 76 patients were included. Clinically meaningful dyspnea (baseline score | 10 points) was present in 49% of patients at 3 months and 46% at 12 months following COVID-19. Between 3 and 12 months post-COVID-19, 24% patients had a clinically meaningful worsening in their dyspnea, 49% had no meaningful change, and 28% had a clinically meaningful improvement in their dyspnea. There was worse sleep, mood, quality of life, and frailty in patients with clinically meaningful dyspnea at 12 months post-COVID infection compared to patients without dyspnea. There was no difference in PFT findings, troponin, or BNP comparing patients with and without clinically meaningful dyspnea at 12 months. Severity of dyspnea and depressive symptoms at 3 months predicted severity of dyspnea at 12 months. Conclusions Post-COVID dyspnea is common, persistent, and negatively impacts quality of life. Mood abnormalities may play a causative role in post-COVID dyspnea in addition to potential cardiorespiratory abnormalities. Dyspnea and depression at initial follow-up predict longer-term post-COVID dyspnea, emphasizing that standardized dyspnea and mood assessment following COVID-19 may identify patients at high risk of post-COVID dyspnea and facilitating early and effective managem
Read more »
Dozens of boats destroyed in Seattle marina fire as arson suspect arrestedBREAKING: A massive fire at a boat storage facility at the Seattle marina destroyed dozens of boats as an arson suspect is arrested.
Read more »
Blizzard says Diablo 4 beta issues have paved the way for a smoother launch | VGCBlizzard says the “rocky start” to Diablo 4’s beta is helping to pave the way for a smoother launch. Players should expect improvements when the test opens to all players this weekend, according to franchise boss Rod Fergusson
Read more »
Fake cash, drugs and shocked faces as police smash their way into 'hell' flatFake cash, drugs gear and shocked faces as police smash their way into 'hell' flat
Read more »
An artificial intelligence approach for predicting death or organ failure after hospitalization for COVID-19: development of a novel risk prediction tool and comparisons with ISARIC-4C, CURB-65, qSOFA, and MEWS scoring systems - Respiratory ResearchBackground We applied machine learning (ML) algorithms to generate a risk prediction tool [Collaboration for Risk Evaluation in COVID-19 (CORE-COVID-19)] for predicting the composite of 30-day endotracheal intubation, intravenous administration of vasopressors, or death after COVID-19 hospitalization and compared it with the existing risk scores. Methods This is a retrospective study of adults hospitalized with COVID-19 from March 2020 to February 2021. Patients, each with 92 variables, and one composite outcome underwent feature selection process to identify the most predictive variables. Selected variables were modeled to build four ML algorithms (artificial neural network, support vector machine, gradient boosting machine, and Logistic regression) and an ensemble model to generate a CORE-COVID-19 model to predict the composite outcome and compared with existing risk prediction scores. The net benefit for clinical use of each model was assessed by decision curve analysis. Results Of 1796 patients, 278 (15%) patients reached primary outcome. Six most predictive features were identified. Four ML algorithms achieved comparable discrimination (P | 0.827) with c-statistics ranged 0.849–0.856, calibration slopes 0.911–1.173, and Hosmer–Lemeshow P | 0.141 in validation dataset. These 6-variable fitted CORE-COVID-19 model revealed a c-statistic of 0.880, which was significantly (P | 0.04) higher than ISARIC-4C (0.751), CURB-65 (0.735), qSOFA (0.676), and MEWS (0.674) for outcome prediction. The net benefit of the CORE-COVID-19 model was greater than that of the existing risk scores. Conclusion The CORE-COVID-19 model accurately assigned 88% of patients who potentially progressed to 30-day composite events and revealed improved performance over existing risk scores, indicating its potential utility in clinical practice.
Read more »